Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Polysomnography Study to Assess the Efficacy and Safety of ACT-541468 in Adult and Elderly Subjects With Insomnia Disorder
Phase of Trial: Phase III
Latest Information Update: 07 Feb 2019
At a glance
- Drugs Nemorexant (Primary)
- Indications Insomnia
- Focus Registrational; Therapeutic Use
- Sponsors Idorsia Pharmaceuticals
- 07 Feb 2019 According to the Idorsia Pharmaceuticals media release, data from this trial is expected in the first half of 2020.
- 24 Jan 2019 Planned primary completion date changed from 1 Nov 2019 to 1 Oct 2019.
- 11 Jun 2018 Status changed from not yet recruiting to recruiting, according to Idorsia Pharmaceuticals media release.